Migraine DisordersAspirinCaffeineMigraine with AuraMigraine without AuraTryptaminesPlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalHeadacheCentral Nervous System StimulantsHeadache DisordersTension-Type HeadacheTheobromineSumatriptanCoffeePhotophobiaErgotamineCortical Spreading DepressionTiclopidineDihydroergotamineThromboxane B2Platelet AggregationCyclooxygenase InhibitorsDouble-Blind MethodDose-Response Relationship, DrugPizotylineAnalgesicsSalicylatesSerotonin Receptor AgonistsPlatelet Function TestsRyanodineDrug Therapy, CombinationCalciumNaproxenCytochrome P-450 CYP1A2Time FactorsRisk FactorsHeadache Disorders, PrimaryBlood PlateletsHeadache Disorders, SecondaryOphthalmoplegic MigraineProcaineCross-Over StudiesSodium SalicylatePhosphodiesterase InhibitorsTreatment OutcomeDrug InteractionsFibrinolytic AgentsProspective StudiesHyperacusisForamen Ovale, PatentCalcitonin Gene-Related PeptideHemorrhageIbuprofenAsthma, Aspirin-InducedCase-Control StudiesHabituation, PsychophysiologicAnticoagulantsQuestionnairesWarfarinTablets, Enteric-CoatedStrokePain MeasurementCyclooxygenase 1AcetaminophenDipyridamoleMeningeal ArteriesTrigeminal NucleiSarcoplasmic ReticulumBleeding TimeGastrointestinal HemorrhageRyanodine Receptor Calcium Release ChannelProstaglandin-Endoperoxide SynthasesPlatelet ActivationReceptor, Adenosine A2ABeveragesThromboxanesPrevalenceAdministration, OralComorbidityDura MaterThromboxane A2Follow-Up StudiesMuscle ContractionRandomized Controlled Trials as TopicCohort StudiesFlushingThrombosisTrigeminal GanglionCyclooxygenase 2 InhibitorsAdenosine A2 Receptor AntagonistsDrug ResistanceFlunarizineReceptor, Adenosine A1PlacebosRecurrenceVertigoIndomethacinChronic DiseaseEphedrine